Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 25, 2021updated 26 Feb 2021 3:10am

Solano Hematology selects VIPER for clinical trial recruitment

Solano Hematology Oncology has adopted Deep Lens’ artificial intelligence-based platform VIPER to improve patient access to clinical oncology trials.

Solano Hematology Oncology has adopted Deep Lens’ artificial intelligence-based platform VIPER to improve patient access to clinical oncology trials.

The screening and enrolment platform makes use of Cloud-based technology to accelerate the recruitment process for clinical trials.

Oncology care teams at Solano Hematology Oncology in Vallejo and the Cancer Treatment Center of Vacaville will use the VIPER platform.

The integration of VIPER helps to effectively identify, screen and match patients to precision-based clinical oncology trials.

Solano Hematology Oncology and Cancer Treatment Center of Vacaville founder Chainarong Limvarapuss said: “The integration of VIPER into our current workflow for clinical trial recruitment will be a significant step toward more effectively serving cancer patients in the greater Bay Area.

“The ability to identify eligible patients for clinical trials quickly and with ease will remarkably improve the speed by which our patients have access to promising new therapies in development designed to improve their care.”

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Deep Lens noted that over 15,000 oncology clinical trials are recruiting patients, but patient participation is often less than 3%.

The new platform automates this clinical trial screening process and matches patients to the suitable trials using the ingestion and analysis of the customised genomic data, electronic medical records and pathology data.

Deep Lens chief revenue officer Greg Andreola said: “A large majority of cancer patients are identified and diagnosed at community cancer centers like Solano, and we are pleased to be able to provide a solution that may help accelerate access to care for patients in the greater Bay Area.

“The inclusion of VIPER into the clinical trial recruitment process at Solano Hematology Oncology will also help relieve some of the operational constraints related to managing this process, allowing care teams to focus on optimising options and improving care for their patients.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU